Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Lung cancer limited disease

Turrisi A, Glover DJ. Thoracic radiotherapy variables influence on local control in small-cell lung cancer limited disease. Int J Radiat Oncol Biol Phys 1990 19 1473-1479. [Pg.211]

The most commonly used system of staging SCLC was developed originally by the Veterans Administration Lung Cancer Study Group. This system categorizes SCLC into two classifications limited and extensive disease.16... [Pg.1327]

Small cell lung cancer typically presents as extensive disease (approximately 60% to 70% of new cases) and progresses very quickly. Small cell carcinomas are very responsive to chemotherapy and radiation. Radiotherapy became the standard in 1969, when a randomized trial showed that it offered the potential for cure, whereas surgery did not.20 For the vast majority of patients, chemotherapy with or without radiotherapy is the treatment of choice. Even after a complete response to therapy, the cancer usually recurs within 6 to 8 months, and survival time following recurrence is typically short ( 4 months). This yields a typical survival rate of 14 to 20 months for limited disease and 8 to 13 months for extensive disease.33 Table 87-6 illustrates the general treatment path of SCLC. [Pg.1331]

Ettinger DS. Concurrent paclitaxel-containing regimens and thoracic radiation therapy for limited-disease small cell lung cancer. SeminRadiat Oncol 1999 9(2 Suppl 1) 148-150. [Pg.87]

Ettinger DS, Seiferheld WF, Abrams RA, et al. Cisplatin, etoposide, paclitaxel and concurrent hyperfractionated thoracic radiotherapy for patients with limited disease small-cell lung cancer Preliminary results of RTOG 96-09 (abstract 1917). Proc Am Soc Clin Oncol 2000 19 490a. [Pg.212]

Small cell lung cancer (SCLC) includes approximately 20-25% of all cases of lung cancer seen worldwide. SCLC differs from other types of lung cancer in its more aggressive course and its superior responsiveness to chemotherapy and radiotherapy. The main modality of treatment for SCLC is combination chemotherapy. Eor patients with limited disease achieving a major response on chemotherapy, this is usually combined with concurrent thoracic irradiation. Prophylactic whole brain irradiation is often administered to complete responders because of the high probability of CNS relapse with associated morbidity. [Pg.710]

In lung cancer, overexpression of HER-2 is associated with a poor prognosis. Unlike breast carcinoma, HER-2/nen gene amplification in NSCLC is uncommon. However, in advanced lung carcinoma, the Herceptin is positive. Thus, Herceptin may have a role in the treatment of a proportion of patients with this disease, but it is of a limited clinical value, especially in the adjuvant setting. [Pg.287]

The continuing worldwide increase in respiratory disease corresponds to increases in the release of chemicals into the atmosphere. Respiratory irritation, sensitization, asthma, RADS, and lung cancer can be attributed to numerous single chemicals whose toxicological properties are, for the most part, well known. Many unexplained incidences of respiratory disease cannot be attributed to single chemical exposures, but have been shown to occur when exposures are to chemical mixtures that are composed of at least one lipophile and one hydrophile. The sources of such mixtures include diesel exhausts, tobacco smoke, carpet emissions, paint fumes, and cleaning products. Prevention of chemically induced respiratory diseases should include limiting exposures to these chemical mixtures. [Pg.287]

A two-stage classification established by the Veterans Administration Lung Cancer Study Group is widely used in the United States to stage SCLC. Limited disease is classified as disease confined to one hemithorax and to the regional lymph nodes. All other disease is classified as extensive. Approximately 70% of patients initially present... [Pg.2369]

Mutual Chemical was by now up for sale as a delayed consequence of the death of company president H. M. Kaufmann, following several years after his son and heir apparent had succumbed to Hodgkin s disease.38 Tarr, in reply to a mid-1953 inquiry about safe levels from a German chromium producer, opined that the exposure limit in use was based entirely on acute illness and we would not feel safe in assuming that the hazard with respect to lung cancer would be eliminated. But in a memorandum prepared a few months later for the prospective buyers, he put a more positive slant on what amounted to the same conclusion. On the subject of control (control of what is never stated, but lung cancer is obviously intended), he observed that while It is not to be expected that reputable members of the medical profession. .. will undertake to guarantee that the measures adopted are certain to... [Pg.72]

Topotecan (hycamtin) is indicated for previously treated patients with ovarian and small ceU lung cancer. Its significant hematological toxicity has limited its use in combination with other active agents in these diseases (e.g., cisplatin). Promising antitumor activity also has been observed in hematological malignancies, particularly in CML and in myelodysplastic syndromes. [Pg.885]


See other pages where Lung cancer limited disease is mentioned: [Pg.264]    [Pg.39]    [Pg.1328]    [Pg.1332]    [Pg.48]    [Pg.280]    [Pg.501]    [Pg.448]    [Pg.165]    [Pg.108]    [Pg.166]    [Pg.119]    [Pg.19]    [Pg.204]    [Pg.75]    [Pg.75]    [Pg.197]    [Pg.212]    [Pg.339]    [Pg.428]    [Pg.126]    [Pg.651]    [Pg.88]    [Pg.47]    [Pg.301]    [Pg.81]    [Pg.756]    [Pg.195]    [Pg.187]    [Pg.586]    [Pg.698]    [Pg.893]    [Pg.882]    [Pg.1173]    [Pg.44]    [Pg.156]    [Pg.659]    [Pg.217]    [Pg.92]   
See also in sourсe #XX -- [ Pg.1331 ]




SEARCH



Diseases cancer

Lung cancer

Lung disease lungs

© 2024 chempedia.info